hotspot -WSS

hotspot

author：fashion 2025-09-30 22:27:18 - browse：8

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Feng Zhang, Grail founder join forces on new gene editing startup

focus

WSS

Antibiotic resistance nearly killed me, so I'm raising awareness of it

3 medical device trends to watch in 2024

J&J to buy cancer drug developer Ambrx Biopharma

J&J to buy cancer drug developer Ambrx Biopharma

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Biohaven protein

hotspot

hotspot

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Antibiotic resistance and the global rise in human conflict

Wildfire smoke exposes gaps in outdoor worker protections

Chronically ill young patients struggle to find fertility info

In Memoriam: Notable people who died in 2023

Burning questions for the 2024 JPM Healthcare Conference

Medical records are filled with copy

GSK Flovent asthma inhalers replaced by authorized generics

Psychedelics group wrestles with new pharma identity

Lab trade group sues FDA to halt regulation of lab

hotspot

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

New weight loss drugs work. But how can they best be used?

The FDA must approve intranasal treatments for anaphylaxis

Report: NIH

Morgan Health, with ambitious aims, wants you to know it’s still here

JPM: CVS says Medicare Advantage patients are impacting profits

leisure time

hotspot

focus

leisure time